Results 261 to 270 of about 2,872,837 (282)
Some of the next articles are maybe not open access.
202 Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From the Phase 3 ICONIC-LEAD Study
Journal of Investigative DermatologyLawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Joseph F. Merola, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gig Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller +20 moreopenaire +1 more source73600 Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study
Journal of the American Academy of DermatologyJennifer Soung, Mark G. Lebwohl, Adelaide Hebert, Andrew E. Pink, Yuling Shi, Megan Miller-Kassamali, Joseph Cafone, Jingzhi Jiang, Shu Li, Ya-Wen Yang, Lawrence Eichenfield +10 moreopenaire +1 more source0941 Reduction of skin CD8 TRMs in icotrokinra-treated participants with moderate-to-severe plaque psoriasis: Phase 3 ICONIC-LEAD results through week 52
Journal of Investigative DermatologyJ. Angsana, Y. Ren, J. Sendecki, K. Kohler, N. Roscoe, J. Gooco, C. Sisk, T. Lee, C. DeKlotz, M. Miller-Kassamali, J. Cafone, P. Newbold, A. Kannan, M.E. Polak, D. Waterworth, N. Sabins, C. Cuff, K. Eyerich, K. Wolk, R. Sabat, H. Mehta, M. Sarfati, S. Molin, R. Bissonnette +23 moreopenaire +1 more sourcePOS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
Annals of the Rheumatic DiseasesR. Bissonnette, J. Soung, A. Hebert, A. Pink, A. Pinter, Y. Shi, J.F. Merola, M. Miller, J. Cafone, J.Z. Jiang, C. DeKlotz, M. Lebwohl +11 moreopenaire +1 more source091 Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23–receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the Phase 3,
randomized, double-blind, placebo-controlled ICONIC-LEAD trial
Journal of Investigative DermatologyR Bissonette, J Soung, A Hebert, A Pink, A Pinter, Y Shi, J Cafone, J Jiang, J Obeid, MG Lebwohl +9 moreopenaire +1 more source